ATNM Deadline: Rosen Law Firm Urges Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653.
The Allegations: Rosen Law Firm is Investigating the Allegations that Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Misled Investors Regarding its Business Operations.
According to the lawsuit, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Actinium's data from Sierra Trial was unlikely to satisfy the U.S. Food and Drug Administration's ('FDA') guidelines for the acceptance and approval of Actinium's Iomab-B Biologics License Application ('BLA'); (2) the additional analyses, including long-term follow-ups that purportedly demonstrated a trend towards improved Overall Survival ('OS') that Actinium provided to the FDA in an attempt to mitigate the Sierra Trial's poor OS data were unlikely to satisfy the FDA's guidelines for the acceptance and approval of Actinium's Iomab-B BLA; (3) as a result, the FDA would likely refuse to review the Iomab-B BLA or, if it did consider that BLA, that the application in its current form was unlikely to be approved; and (4) as a result, defendants' positive statements about Actinium's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
What Now: You may be eligible to participate in the class action against Actinium Pharmaceuticals, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by May 27, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
MannKind (MNKD) Secures $500M Financing to Advance Inhaled Therapies Pipeline
We recently published . MannKind Corporation (NASDAQ:MNKD) is one of the best healthcare stocks. MannKind Corporation (NASDAQ:MNKD)'s most recent milestone is its push to expand the use of its rapid-acting inhaled insulin, Afrezza, to pediatric patients. In August 2025, the company submitted a supplemental Biologics License Application to the FDA for use in children ages 4–17, supported by positive Phase 3 INHALE-1 trial results presented at major diabetes conferences. A regulatory decision is expected in Q4 2025. Clinical data from both pediatric (INHALE-1) and adult (INHALE-3) studies have reinforced Afrezza's efficacy and safety across age groups. These advances have also helped the business gain attention among investors looking at the best healthcare stocks. Beyond Afrezza, MannKind Corporation (NASDAQ:MNKD) is advancing its pipeline in respiratory and rare diseases. MNKD-101, an inhaled clofazimine for nontuberculous mycobacterial lung disease, is progressing ahead of schedule in its global Phase 3 ICoN-1 trial. MNKD-201, a therapy for idiopathic pulmonary fibrosis, is set to enter Phase 2 testing by the end of 2025. Copyright: nicoletaionescu / 123RF Stock Photo To support these initiatives, the business secured up to $500 million in non-dilutive financing from Blackstone in August 2025. This funding will accelerate the potential launch of pediatric Afrezza, expand its commercial capabilities, and advance its clinical programs. Together, these developments position MannKind Corporation (NASDAQ:MNKD) for growth in both diabetes care and specialty lung disease markets. While we acknowledge the potential of MNKD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
an hour ago
- Yahoo
ImmunityBio (IBRX) Reports 60% Revenue Growth as ANKTIVA Adoption Accelerates
We recently published . ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best healthcare stocks. ImmunityBio, Inc. (NASDAQ:IBRX) is among the best healthcare stocks. It is a clinical-stage biotech company developing advanced immunotherapies and vaccines targeting cancers and infectious diseases by activating immune cells such as natural killer and T cells. A key recent milestone is the FDA-approved immunotherapy drug ANKTIVA for bladder cancer, specifically for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS). ANKTIVA, designated a Breakthrough Therapy, is expanding its clinical use, notably with the Michael E. DeBakey VA Medical Center in Houston becoming one of the first VA hospitals to administer the treatment to veterans, a population at higher bladder cancer risk. In Q2 2025, ImmunityBio, Inc. (NASDAQ:IBRX) reported a 60% revenue growth quarter-over-quarter, reaching $26.4 million and a year-to-date total of approximately $43 million. This growth is driven by increased commercial momentum post-approval and supported by an $80 million capital raise in July 2025 to fuel ongoing development and expansion. ImmunityBio, Inc. (NASDAQ:IBRX) is transitioning from a clinical-stage biotech to a commercial-stage company with ANKTIVA's expanding adoption, including recent UK regulatory approval for ANKTIVA plus BCG. The drug addresses an underserved cancer indication with the potential to reduce invasive treatments like cystectomy, backed by clinical data showing durable bladder preservation up to 36 months in responders. While we acknowledge the potential of IBRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
This week in business: Big perks, big layoffs, and a few PR face-plants
This week's business headlines reflected a market still finding its footing in a post-pandemic, tech-driven, politically charged economy. The themes were clear: Companies are refining strategies to capture new audiences, governments are making moves with high economic stakes, and consumer behavior is forcing industries to adapt. Employers need help managing workers who are taking second jobs The FDA is warning you not to use this cookware—it could be poisoning your food with lead New study finds coffee is good for you, but there's a catch In finance, the credit-card-rewards arms race saw a surprising twist—while premium travel cards have leaned on hefty fees and luxury perks, one player is going in the opposite direction, offering big benefits at no annual cost. Meanwhile, the housing market showed early signs of strain in certain U.S. hot spots, with negative equity creeping up in Florida and Texas. The corporate world saw significant leadership changes and some unsettling labor trends. Layoff numbers for 2025 have already surpassed all of last year, driven by a mix of government spending cuts, tariffs, and AI-driven restructuring. Consumer industries faced their own disruptions—from tipping declines in restaurants to public backlash over a beauty brand's ad campaign. Here are the 10 biggest business stories of the week. Capital One ups the ante with no-fee travel card perks In a bold move against high-fee competitors like Amex Platinum and Chase Sapphire Reserve, Capital One is adding new perks like $100 travel credits, vacation rental access, and Hertz Five Star status to its no-annual-fee cards, allowing them to better compete with their for-fee rivals. FDA recall: Contaminated soaps pose sepsis risk DermaRite Industries recalled several soap and skincare products after finding they were contaminated with Burkholderia cepacia, a bacterium that can cause life-threatening infections in immunocompromised individuals. Consumers are advised to destroy affected products immediately. Underwater mortgages rise in Florida and Texas Housing data shows negative equity is increasing in pandemic boomtowns like Cape Coral and Austin, though still far from 2009 crisis levels. Many of the affected homeowners bought during the 2022–2024 market peak. Whitmer confronts Trump over tariff impact on auto industry Michigan Gov. Gretchen Whitmer met privately with President Trump to warn that new tariffs could damage the state's auto sector. Automakers report billions in added costs that threaten factory investments and jobs. U.S. layoffs hit 800,000 in 2025—already exceeding last year's total Job cuts have surged 75% over the last year, driven by government spending reductions, tariffs, and AI automation. The hardest-hit sectors include government, tech, and retail. Tipping in America falls to a 7-year low Restaurant management platform Toast reports the average tip at full-service restaurants has slipped to 19.1%, with California at the bottom (17.3%) and Delaware leading (21.4%). Analysts cite 'tipflation' and shifting consumer habits. LinkedIn names top AI-focused colleges In its first-ever ranking, LinkedIn highlights schools producing the most AI-ready graduates. Caltech and MIT lead both in AI job placement and in graduates with AI skills. Threads nears X's mobile user numbers Meta's Threads hit 400 million monthly active users and 115 million daily mobile users, narrowing the gap with Elon Musk's X to just 17 million in the U.S. daily mobile audience. E.l.f. Beauty faces backlash over Matt Rife ad The cosmetics brand is under fire for casting stand-up comic Matt Rife, criticized for past jokes about domestic violence and trans people. E.l.f.'s statement acknowledged 'missing the mark' but stopped short of an apology. Life360 appoints Lauren Antonoff as CEO Location-tracking company Life360 promoted COO Lauren Antonoff to CEO, succeeding cofounder Chris Hulls. The company is eyeing international expansion and deeper integration with everyday family life. This post originally appeared at to get the Fast Company newsletter:
